General Clinical Study of AJG555 in Pediatric Patients With Chronic Constipation

General Clinical Study of AJG555 in Pediatric Patients With Chronic Constipation

This baseline-controlled, open-label, multicenter study evaluates the efficacy and safety of AJG555 orally administered for 2 weeks in pediatric participants with chronic constipation. The safety and efficacy of 12 weeks of administration will also be evaluated.

Inclusion Criteria:

Main Inclusion Criteria:

• Participants with chronic constipation
• Age: 2 years old or older and 14 years old or younger (at the time of the informed consent)
• Gender: N/A

Exclusion Criteria:

Main Exclusion Criteria:

• Participants with organic constipation or participants suspected of having organic constipation
• Participants with symptomatic constipation or participants suspected of having symptomatic constipation
• Participants with drug-induced constipation or participants suspected of having drug-induced constipation